A group of congressional leaders are calling on the Patent and Trademark Office to reassert its role in reviewing and deflecting the practices drug companies use to keep prices high and block more affordable alternatives from entering the market, particularly by strengthening the process of inter partes review (IPR). In a Sept. 16 letter to PTO , the lawmakers say the office’s IPR process has been weakened by administrative changes that have led the office to frequently deny petitions from...